scholarly journals Diffi culties of diff erential diagnosis in functional dyspepsia

2021 ◽  
Vol 99 (3) ◽  
pp. 208-212
Author(s):  
A. A. Sheptulin ◽  
S. S. Kardasheva ◽  
A. A. Kurbatova
Keyword(s):  
Functional Dyspepsia ◽  
Epigastric Pain ◽  
Diagnostic Errors ◽  
Postprandial Fullness ◽  
Comprehensive Examination ◽  
Early Satiation ◽  
Rome Iv

Dyspepsia syndrome is understood as a complex of symptoms, including epigastric pain and epigastric burning, postprandial fullness and early satiation. In cases when organic diseases cannot be detected in patients as the cause of these symptoms, the term functional dyspepsia (FD) should be used. Rome IV criteria of FD in the absence of “alarm symptoms” consider it possible to make a diagnosis of FD without instrumental examination (fi rst of all, without esophagogastroduodenoscopy). The recommendations of the Russian Gastroenterological Association emphasize that this approach leads to serious diagnostic errors, and therefore the diagnosis of PD should be considered as a diagnosis of exclusion, which can be made only after a comprehensive examination of patients.

scholarly journals Topical Mastic Oil for Treatment of Functional Dyspepsia: A Randomized Triple-Blind Controlled Trial

2021 ◽  
Vol 10 ◽  
pp. 1965
Author(s):  
Mahsa Baradaran Sattarzadeh ◽  
Asie Shojaii ◽  
Mohssen Nassiri Toosi ◽  
Mehri Abdollahi-Fard ◽  
Foroogh Alborzi Avanaki ◽  
...  
Keyword(s):  
Functional Dyspepsia ◽  
Epigastric Pain ◽  
Controlled Trial ◽  
Study Groups ◽  
Control Group ◽  
Test Results ◽  
Postprandial Fullness ◽  
Friedman's Test ◽  
Early Satiation ◽  
Better Than

Background: The main goal of the present study was to evaluate the effect of topical mastic oil, compared to placebo on treatment of functional dyspepsia (FD). Materials and Methods: Sixty-three patients with FD were included. Thirty-two subjects received the topical mastic oil (10 drops/TDS after meal) with massage and 31 patients received topical sesame oil with massage. Both groups received pantoprazole (40 mg daily) along with oil and massage. The severity of early satiation, postprandial fullness, epigastric pain and epigastric burning was assessed after 4 weeks using the Visual Analogue Scale (VAS) as well as frequency of symptoms. Satisfaction with the treatment was also assessed using a researcher-made questionnaire. Changes in the severity of symptoms were evaluated by Friedman’s test. Results: Mean and standard deviation of age of the subjects were equal to 36.95±13.64 and 50 (79.4%) patients were female. Both groups experienced a significant decrease in the severity of all the four symptoms (P<0.001). The percentage of decrease in the severity of early satiation was significantly higher in the mastic group than the control group (76.03±34.91% vs. 37.24±38.86%, P=0.003). No significant differences were found in the percentage of decrease in the severity of postprandial fullness, epigastric pain and burning between the study groups (P=0.05, 0.06, and 0.13, respectively). The frequency of symptoms was decreased similarly in both groups. Satisfaction with the treatment was reported to be significantly higher in the mastic group than the sesame group (P=0.01). There were no intolerable side effects in both groups. Conclusion: Mastic oil reduced early satiation better than the placebo. In addition, satisfaction with the treatment was higher in the mastic group than the sesame group. [GMJ.2021;10:e1965]

scholarly journals The association between eating rate and functional dyspepsia in Iranian adults

2020 ◽  
Author(s):  
Parvane Saneei ◽  
Ammar Hassanzadeh Keshteli ◽  
Hamid Rasad ◽  
Hamed Daghaghzadeh ◽  
Awat Feizi ◽  
...  
Keyword(s):  
Functional Dyspepsia ◽  
Epigastric Pain ◽  
Large Population ◽  
Cross Sectional Study ◽  
Dietary Habit ◽  
Eating Rate ◽  
Cross Sectional ◽  
Postprandial Fullness ◽  
Gastrointestinal Health ◽  
Early Satiation

Abstract Objective: This study aimed to investigate the association between eating rate and functional dyspepsia (FD) in a large population of Iranian adults.Methods: In this cross-sectional study, we assessed eating rate of 4763 Iranian adults using a dietary habit questionnaire. We used a modified validated version of the Rome III questionnaire to assess gastrointestinal health. FD was defined as having one or more of the following characteristics: bothersome postprandial fullness, early satiation and/or epigastric pain or epigastric burning. Needed information on meal frequency, meal regularity, intra-meal fluid drinking as well as on other potential confounders was obtained by using a pre-tested questionnaire.Results: Functional dyspepsia was prevalent in 15.2% (n=703) of the studied population. Lunch and total eating rate was associated with greater odds of having FD(OR: 1.37; 95% CI: 1.04-1.8) and (OR: 1.45; 95% CI: 1-2.11), respectively). However, this relationship weakened after adjusting for confounding factors. No significant relationship was found between dinner eating rate and FD in both crude and adjusted models (OR: 1.23; 95% CI: 0.83-1.51). There was no significant relation between lunch, dinner or total eating rate and risk of postprandial fullness, early satiation or epigastric pain either in crude or adjusted models. Eating rate was not related to severity or frequency of FD components.Conclusions: Fast eating was associated with greater odds of FD. However, there was no association between fast eating with postprandial fullness and epigastria pain. Further studies, particularly prospective ones, are required to confirm these relations.

scholarly journals DA-9701 (Motilitone): A Multi-Targeting Botanical Drug for the Treatment of Functional Dyspepsia

2018 ◽  
Vol 19 (12) ◽  
pp. 4035 ◽  
Author(s):  
Mirim Jin ◽  
Miwon Son
Keyword(s):  
Functional Dyspepsia ◽  
Serotonin Receptors ◽  
Epigastric Pain ◽  
Herbal Medicines ◽  
Gastrointestinal Disorder ◽  
Clinical Results ◽  
Promising Alternative ◽  
Postprandial Fullness ◽  
Botanical Drug ◽  
Upper Abdomen

Functional dyspepsia (FD) is the most common functional gastrointestinal disorder (FGID). FD is characterized by bothersome symptoms such as postprandial fullness, early satiety, and epigastric pain or burning sensations in the upper abdomen. The complexity and heterogeneity of FD pathophysiology, which involves multiple mechanisms, make both treatment and new drug development for FD difficult. Current medicines for FD targeting a single pathway have failed to show satisfactory efficacy and safety. On the other hand, multicomponent herbal medicines that act on multiple targets may be a promising alternative treatment for FD. DA-9701 (Motilitone), a botanical drug consisting of Corydalis Tuber and Pharbitidis Semen, has been prescribed for FD since it was launched in Korea in 2011. It has multiple mechanisms of action such as prokinetic effects, fundus relaxation, and visceral analgesia, which are mediated by dopamine D2 and several serotonin receptors involved in gastrointestinal (GI) functions. In clinical studies, DA-9701 has been found to be beneficial for improvement of FD symptoms and GI functions in FD patients, while showing better safety compared to that associated with conventional medicines. In this review, we provide updated information on the pharmacological effects, safety, and clinical results of DA-9701 for the treatment of FGIDs.

scholarly journals A Randomized Controlled Study of Efficacy and Safety Profile of Levosulpiride and Itopride in Functional Dyspepsia

2020 ◽  
Vol 5 (2) ◽  
pp. 50-56
Author(s):  
Ganesh Narain Saxena ◽  
Saumya Mathur
Keyword(s):  
Functional Dyspepsia ◽  
Safety Profile ◽  
Epigastric Pain ◽  
Randomized Controlled Study ◽  
Controlled Study ◽  
Efficacy And Safety ◽  
Early Satiety ◽  
Postprandial Fullness ◽  
Presenting Symptoms ◽  
Randomized Controlled

ABSTRACT Introduction Dyspepsia is a clinical problem of considerable magnitude for the healthcare system due to the high prevalence and chronic and recurrent nature of symptoms. Earlier dyspepsia was referred to as a heterogeneous group of symptoms in the upper abdomen and retrosternal which are related to ingestion of meals and include heartburn, regurgitation, epigastric pain, epigastric burning, postprandial fullness/distension, early satiety, bloating, belching, anorexia, nausea, and vomiting. This has prompted the search for newer agents with equal efficacy but lower side effect potential such as levosulpiride and itopride. Aim and objectives To evaluate and compare the efficacy of the newer drugs like levosulpiride and itopride in functional dyspepsia. Observations and results The most common presenting symptoms in the present study were epigastric fullness (81%), upper abdominal pain (55%), early satiety (52%), and epigastric burning (45%). Less common symptoms were bloating (27%), belching (11%), heartburn (10%), and nausea (8%). Conclusion Drugs, itopride and levosulpiride, were equally effective in ameliorating different symptoms of functional dyspepsia at the end of 4 weeks of treatment. There was a significant reduction in mean global symptom score (GSS) and mean duration score and mean score of severity in follow-up visits at the 2nd and 4th week from the day of presentation (p value < 0.05). How to cite this article Saxena GN, Mathur S. A Randomized Controlled Study of Efficacy and Safety Profile of Levosulpiride and Itopride in Functional Dyspepsia. J Mahatma Gandhi Univ Med Sci Tech 2020;5(2):50–56.

Treatment of Patients with Refractory Functional Dyspepsia Using Nardostachys jatamansi (D.Don) DC. Hydroalcoholic Extract: A Case Series

2019 ◽  
Author(s):  
Mohaddese Mirzapour ◽  
Morteza Mojahedi ◽  
Javad Shokri ◽  
Soraia Khafri ◽  
Zahra Memariani
Keyword(s):  
Functional Dyspepsia ◽  
Rating Scale ◽  
Case Series ◽  
Self Report ◽  
Postprandial Fullness ◽  
Gastrointestinal Symptom Rating Scale ◽  
End Of Treatment ◽  
Nardostachys Jatamansi ◽  
Study Population ◽  
Early Satiation

Functional dyspepsia (FD) is a highly prevalent condition with high impact on healthcare costs. Considering the complimentary therapies options like phytotherapy, this study aimed to investigate the efficacy and safety of Nardostachys jatamansi (D.Don) DC. extract in sixteen FD patients. The subjects received capsules of 500 mg N. Jatamansi, 3 times daily before meals for 30 days. The severity of early satiation and postprandial fullness were assessed by self-report of improvement at least 50% of symptoms and other FD symptoms assessed by Gastrointestinal Symptom Rating Scale (GSRS) before intervention and at end of treatment. The mean GSRS score level decreased significantly after intervention among study population. Five patients had chief complaint of early satiety and post prandial fullness who all of them reported 50% improvement. According to the results N. jatamansi seems to be effective in patients with refractory FD. Randomized clinical studies seem to be required.

scholarly journals Efficacy of Trimebutine Maleate in the Treatment of Functional Dyspepsia in Childhood

2013 ◽  
Vol 33 (2) ◽  
pp. 158-162
Author(s):  
Alexander A Nijevitch ◽  
Elsa N Akhmadeeva ◽  
Valery U Sataev ◽  
Bulat Idrisov
Keyword(s):  
Functional Dyspepsia ◽  
Epigastric Pain ◽  
Functional Gastrointestinal Disorders ◽  
Therapeutic Interventions ◽  
Therapeutic Drug ◽  
Limited Data ◽  
Opioid Agonist ◽  
Postprandial Fullness ◽  
Trimebutine Maleate ◽  
Increasing Demand

Peripheral μ-, k- and δ-opioid agonist trimebutine maleate is considered to be an effective therapeutic drug for the treatment of functional gastrointestinal disorders. Ninety-two paediatric outpatients (12- 17 year-old) suffering from functional dyspepsia (epigastric pain and meal-induced dyspeptic symptoms) were enrolled in a prospective openlabel study. For ethical reasons, no placebo group was included. Patients were treated with trimebutine maleate (200 mg three times daily). After a 3-week treatment there was a significant decrease in scores of epigastric pain (p<0.05), postprandial fullness (p<0.05), early satiety (p<0.05), nausea (p<0.05) and belching (p<0.05). The treatment regimen was well tolerated and demonstrated a good compliance. In conclusion, we postulate that trimebutine maleate is an effective medication for relief of main symptoms associated with functional dyspepsia syndrome in childhood. Because of the limited data on therapeutic interventions in functional dyspepsia in childhood and increasing demand for therapies to treat this disorder, further evaluation of the efficacy of trimebutine treatment for children is certain. DOI: http://dx.doi.org/10.3126/jnps.v33i2.7229   J Nepal Paediatr Soc. 2013; 33(2):158-162

scholarly journals Correlation between sleep impairment and functional dyspepsia

2020 ◽  
Vol 48 (7) ◽  
pp. 030006052093716
Author(s):  
Zhen-Peng Huang ◽  
Si-Meng Li ◽  
Tong Shen ◽  
Yuan-Yuan Zhang
Keyword(s):  
Sleep Quality ◽  
Functional Dyspepsia ◽  
Sleep Disturbances ◽  
Disease Course ◽  
Short Term ◽  
Sleep Impairment ◽  
Symptom Frequency ◽  
Early Satiation ◽  
Rome Iv

Objective Sleeping habits may greatly impact the prevalence of functional dyspepsia (FD). This study examined relationships between aspects of sleep impairment and FD. Methods This prospective study included university student volunteers. Following enrolment, FD was diagnosed based on the Rome IV criteria, dividing participants into an FD group or controls. The FD group was further subdivided into long-term (disease course >6 months) and short-term (disease course 3–6 months) FD groups. Participants completed the Pittsburgh Sleep Quality Index (PSQI), the Rome IV Diagnostic Questionnaire for Gastrointestinal Disorders in Adults, and a visual analogue scale (VAS). Results Out of 418 participants in total, sleep quality, latency, and duration, habitual sleep efficiency, sleep disturbances, sleep medication use, daytime dysfunction, and PSQI scores were higher in the FD groups versus controls. Components of PSQI scores emerged as risk factors, and were higher in the long-term versus short-term dyspepsia group. Moreover, these components were positively correlated with frequency/severity of postprandial distress syndrome and early satiation. Total PSQI scores were positively correlated with VAS scores. Conclusion Several PSQI components are associated with FD occurrence, symptom frequency, and symptom severity.

scholarly journals Nerve growth factor and Tropomyosin receptor kinase A are increased in the gastric mucosa of patients with functional dyspepsia

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Haitao Shi ◽  
Shanshan Zhu ◽  
Bin Qin ◽  
Lianli Wang ◽  
Juan Yang ◽  
...  
Keyword(s):  
Nerve Growth Factor ◽  
Growth Factor ◽  
Gastric Mucosa ◽  
Epigastric Pain ◽  
Control Group ◽  
Receptor Kinase ◽  
Postprandial Fullness ◽  
Dyspeptic Symptoms ◽  
Early Satiation ◽  
Kinase A

Abstract Background Nerve growth factor (NGF) and enteric glial cells (EGCs) are associated with visceral hypersensitivity and gastrointestinal motility disorder, which may represent the pathogenesis of functional dyspepsia (FD). This study aimed to investigate the expression of NGF, its high affinity receptor tropomyosin receptor kinase A (TrkA) and the EGC activation marker glial fibrillary acidic protein (GFAP) in the gastric mucosa of patients with FD and the association of these proteins with dyspeptic symptoms. Methods Gastric mucosal biopsies taken from 27 FD patients (9 epigastric pain syndrome (EPS) patients, 7 postprandial distress syndrome (PDS) patients and 11 EPS overlap PDS patients) and 26 control subjects were used for analysis. The expression of NGF, TrkA and GFAP was examined, and the association of these proteins with dyspeptic symptoms, including epigastric pain, postprandial fullness, early satiation and epigastric burning, was analysed. Results The expression levels of NGF, TrkA, and GFAP in the gastric mucosa were significantly higher in the EPS group, the PDS group, and the EPS overlap PDS group than in the healthy control group. There was no significant difference between the FD subgroups. TrkA colocalized with GFAP, which indicated that TrkA was localized to EGCs, and the expression of TrkA in EGCs was significantly higher in the FD group than in the control group. Changes in the expression of NGF, TrkA, and GFAP were positively correlated with epigastric pain, postprandial fullness and early satiation but had no significant relationship with epigastric burning. Conclusions The increased expression of gastric NGF, TrkA and GFAP might be involved in FD pathophysiology and symptom perception.

scholarly journals Dispepsia funcional y gastroparesia: ¿dos entidades superpuestas? De la fisiopatología a la terapéutica

2021 ◽  
Vol 51 (2) ◽  
Author(s):  
María Mercedes Manresa ◽  
Paula Cecilia Carboné ◽  
Guillermina Diez
Keyword(s):  
Gastric Emptying ◽  
Functional Dyspepsia ◽  
Current Knowledge ◽  
Medical Condition ◽  
Epigastric Pain ◽  
Gastrointestinal Microbiota ◽  
Gastrointestinal Infections ◽  
Presumptive Diagnosis ◽  
Postprandial Fullness ◽  
Neuromuscular Abnormalities

Functional dyspepsia and gastroparesis represent the most common sensory-motor disorders of the upper gastrointestinal tract. Scientific advances in the last decade have shown that there is significant overlap between them. This review aims to address current knowledge about their pathophysiology, diagnosis and treatment. Functional dyspepsia is a medical condition that is characterized by one or more of the following symptoms: early satiety, postprandial fullness, and epigastric pain or burning. The pathophysiological mechanisms involved are: the gastroduodenal motility and sensory abnormalities, the immune dysfunction, the duodenal inflammation, the gastrointestinal infections, the alterations in the gastrointestinal microbiota and the dysfunction of the gut-brain axis. The Rome IV criteria make possible to establish a presumptive diagnosis of functional dyspepsia in most patients, although it continues to be a diagnosis of exclusion that requires the performance of an upper digestive video endoscopy to confirm it. The recommended therapeutic options are: the eradication of Helicobacter pylori, the proton pump inhibitors, the tricyclic antidepressants and prokinetics. Gastroparesis is a chronic disorder characterized by delayed gastric emptying in the absence of a mechanical obstruction. The pathophysiology is caused by neuromuscular abnormalities of gastric motor function. Gastric emptying scan is the current gold standard for diagnosis. The mainstays of treatment are restoration of hydration and nutrition, and pharmacological treatment with prokinetics and antiemetics.

scholarly journals Prevalence of dyspeptic symptoms and heartburn of adults in Belo Horizonte, Brazil

2017 ◽  
Vol 54 (1) ◽  
pp. 46-50 ◽  
Author(s):  
Alessandra Maciel ALMEIDA ◽  
Luísa Alvarenga Guerra MARTINS ◽  
Patrícia Liz Terenzi CUNHA ◽  
Viviane Willig BRASIL ◽  
Lucas Galuppo Fernandes FÉLIX ◽  
...  
Keyword(s):  
Functional Dyspepsia ◽  
Eating Habits ◽  
Epigastric Pain ◽  
Pain Syndrome ◽  
Postprandial Fullness ◽  
Epigastric Pain Syndrome ◽  
Dyspeptic Symptoms ◽  
Rome Iii ◽  
Belo Horizonte ◽  
Social Demographic

ABSTRACT BACKGROUND Medical literature has shown dyspepsia and heartburn-related symptoms occur among 15% to 40% of the population. These symptoms can occur at any age and are more prevalent in women. OBJECTIVE Investigate the prevalence of dyspeptic symptoms and heartburn among individuals over 18. METHODS Individuals over 18 were randomly selected in public venues in Belo Horizonte/MG to participate. A standardized questionnaire that included questions related to social-demographic characteristics, eating habits, digestive symptoms, medical appointments, medications, exams, previous surgeries and comorbidities was applied. A questionnaire about functional dyspepsia diagnosis (Rome III) was also applied. RESULTS A total of 548 individuals were interviewed. Among these, 58.4% were women, 59.3% were white, 55.9% were single and the average age was 36 years. Within this group, 376 individuals (68.6%) declared to have some symptom and/or use medication to relieve dyspepsia symptoms, and for these patients were applied the Rome III questionnaire. Based on the diagnostic criteria for the questionnaire proposed by the Rome III consensus, the symptom of postprandial fullness was reported by 6.7% of the individuals, early satiety (3.5%) and epigastric pain (10.6%). The overlap of these symptoms was very frequent. The prevalence of functional dyspepsia was 10.6% (postprandial discomfort syndrome (8.2%) and epigastric pain syndrome (2.4%). Among all participants, 52.5% reported heartburn, and 11.1% presented this symptom at least once a week. The most used drug was omeprazole. CONCLUSION The prevalence of dyspeptic symptoms and heartburn among a Brazilian adult urban population is similar to those described in other countries.

Sign in / Sign up

Export Citation Format

Share Document